BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 11376405)

  • 21.
    Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of thyroglobulin changes for the efficacy of thyroid remnant ablation.
    Savelli G; Chiti A; Rodari M; Schreiner F; Maccauro M; Aliberti G; Gerali A; Bombardieri E
    Tumori; 2001; 87(1):42-6. PubMed ID: 11669557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
    Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
    Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
    Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
    Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
    Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.
    Robbins RJ; Tuttle RM; Sonenberg M; Shaha A; Sharaf R; Robbins H; Fleisher M; Larson SM
    Thyroid; 2001 Sep; 11(9):865-9. PubMed ID: 11575856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
    Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
    J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma.
    Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC; Cho BY; Koh CS
    J Nucl Med; 1997 Aug; 38(8):1191-5. PubMed ID: 9255147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
    J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac blood pool activity on postablation radioiodine imaging.
    Aktaş A; Kocabaş B; Erhamamci S; Gençoğlu A; Liman C
    Ann Nucl Med; 2015 Feb; 29(2):170-6. PubMed ID: 25381484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.